Relay Therapeutics and Praxis Precision Medicines List on Nasdaq
What happened
Relay Therapeutics and Praxis Precision Medicines were listed on the Nasdaq stock exchange on October 1, 2026. A comparison of the two mid-cap healthcare companies showed that Praxis Precision Medicines has a consensus target price of $630.42, while Relay Therapeutics has a consensus target price of $25.92. Analysts noted that Praxis Precision Medicines has a stronger consensus rating and higher probable upside than Relay Therapeutics.
From themarketsdaily.com
Why it matters
The listing of these companies provides public access to their financial metrics, including top-line revenue, earnings per share, and net margins. The detailed comparison of valuation and risk suggests that investment decisions may be influenced by the differing profitability and volatility of the two companies.
From themarketsdaily.com
Who's involved
- Relay TherapeuticsA mid-cap healthcare company listed on the Nasdaq stock exchange
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Relay TherapeuticsSpeculative
Relay Therapeutics' market price or competitive position could be negatively affected by detailed financial comparisons of its business.
Keep exploring
The entities involved
-
Relay Therapeutics
company in Cambridge, United States
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- Praxis Precision Medicines listed its shares on the Nasdaq stock exchange on July 17, 2026.
- Parabilis Medicines debuted on Nasdaq, achieving IPO haul surpassing Moderna's, while its product received FDA fast-track designation. Regeneron also acquired shares.
- Privia Health Group, Inc. shares are listed on the Nasdaq exchange, and Citigroup reissued a buy rating on the stock.